The addition of aromatase inhibitors to ovarian stimulation is a strategy whichhas been successfully used in breast cancer patients to reduce estradiol levelsduring stimulation (Oktay etal., 2005; Azim et al.,2008; Oktay et al.,2015). This evidence concerns the gene CYP19A1 and breast carcinoma.